Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02626520 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla
A Phase 2 study, sponsored by Essentia Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT02626520: Clinical Trial Phase 2 study, sponsored by Essentia Health.
NCT02626520 is a Phase 2 study that was terminated before completion, run by Essentia Health. The registered enrollment target is 11 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02626520, a Phase 2 study, was terminated before completion, sponsored by Essentia Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
Patients diagnosed with pancreatic cancer without clinically detectable metastatic disease will be treated with standardized systemic chemotherapy, followed by chemoradiation, and then surgical resection for those with resectable or borderline resectable disease. The primary endpoint is disease-free survival at 1 yr from initiation of treatment.
Primary Outcome
Percentage of patients alive and free of detectable disease 1 yr from start of treatment
Interventions
- DRUG Gemcitabine and nanoparticle albumin bound paclitaxel
- DRUG 5-fluorouracil and irinotecan
- RADIATION Preoperative chemoradiation
- PROCEDURE Definitive resection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2016-05-11 |
| Est. Completion | 2017-09-14 |
| Phase | Phase 2 |
Why NCT02626520 stopped before completion
NCT02626520 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 4 interventions - of which Gemcitabine and nanoparticle albumin bound paclitaxel is the first listed.
NCT02626520 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02626520 about?
NCT02626520 is a clinical study titled "Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla". Patients diagnosed with pancreatic cancer without clinically detectable metastatic disease will be treated with standardized systemic chemotherapy, followed by chemoradiation, and then surgical resection for those with resectable or borderline resectable disease. The primary endpoint is disease-free...
What is the current status of trial NCT02626520?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2016-05-11. Estimated completion is 2017-09-14.
What interventions are being tested in trial NCT02626520?
The interventions under investigation include: Gemcitabine and nanoparticle albumin bound paclitaxel (DRUG), 5-fluorouracil and irinotecan (DRUG), Preoperative chemoradiation (RADIATION), Definitive resection (PROCEDURE).
Who is sponsoring clinical trial NCT02626520?
This trial is sponsored by Essentia Health, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02626520's enrollment target sits among peer trials
11 1967th of 2000 higher than 33 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI